Tyrosine kinase inhibitors as novel drugs for the treatment of diabetes

Prada, Patricia O.; Saad, Mario J. A.

Advanced search

Search - Use quotation marks to get a more specific result

Index

Field of knowledge

Start date

Betweenand

(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Tyrosine kinase inhibitors as novel drugs for the treatment of diabetes

Full text
Author(s):	Prada, Patricia O. ^[1] ; Saad, Mario J. A. ^[2] Total Authors: 2
Affiliation:	^[1] Univ Estadual Campinas. UNICAMP ^[2] Univ Estadual Campinas. UNICAMP Total Affiliations: 2
Document type:	Review article
Source:	EXPERT OPINION ON INVESTIGATIONAL DRUGS; v. 22, n. 6, p. 751-763, JUN 2013.
Web of Science Citations:	1
Abstract
Introduction: Some inhibitors of tyrosine kinase, as imatinib, erlotinib and sunitinib have antihyperglycemic effects but the mechanisms are not totally clear. Areas covered: It is well established that insulin resistance and beta-cell failure are hallmarks of type 2 diabetes mellitus (DM2). The present review will discuss the molecular mechanisms that account for insulin resistance and beta-cell failure in DM2, and also the effect of tyrosine kinase inhibitors in these processes. Expert opinion: A better understanding of how these drugs improve the two most important mechanisms of DM2 associated with suggestions of clinical studies will lead to improve the treatment of this disease. (AU)

FAPESP's process:	12/10338-6 - The regulation of Clk2 and IKK epsilon in the hypothalamus of obese mice
Grantee:	Patrícia de Oliveira Prada
Support Opportunities:	Regular Research Grants

Short URL